↓ Skip to main content

Rilmenidine suppresses proliferation and promotes apoptosis via the mitochondrial pathway in human leukemic K562 cells

Overview of attention for article published in European Journal of Pharmaceutical Sciences, January 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (81st percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

news
1 news outlet

Citations

dimensions_citation
9 Dimensions

Readers on

mendeley
13 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Rilmenidine suppresses proliferation and promotes apoptosis via the mitochondrial pathway in human leukemic K562 cells
Published in
European Journal of Pharmaceutical Sciences, January 2016
DOI 10.1016/j.ejps.2015.10.017
Pubmed ID
Authors

Tatjana Srdic-Rajic, Katarina Nikolic, Milena Cavic, Ivana Djokic, Branislava Gemovic, Vladimir Perovic, Nevena Veljkovic

Abstract

Imidazoline I1 receptor signaling is associated with pathways that regulate cell viability leading to varied cell-type specific phenotypes. We demonstrated that the antihypertensive drug rilmenidine, a selective imidazoline I1 receptor agonist, modulates proliferation and stimulates the proapoptotic protein Bax thus inducing the perturbation of the mitochondrial pathway and apoptosis in human leukemic K562 cells. Rilmenidine acts through a mechanism which involves deactivation of Ras/MAP kinases ERK, p38 and JNK. Moreover, rilmenidine renders K562 cells, which are particularly resistant to chemotherapeutic agents, susceptible to the DNA damaging drug doxorubicin. The rilmenidine co-treatment with doxorubicin reverses G2/M arrest and triggers apoptotic response to DNA damage. Our data offer new insights into the pathways associated with imidazoline I1 receptor activation in K562 cells suggesting rilmenidine as a valuable tool to deepen our understanding of imidazoline I1 receptor signaling in hematologic malignancies and to search for medicinally active agents.

Mendeley readers

The data shown below were compiled from readership statistics for 13 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 13 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 4 31%
Researcher 3 23%
Lecturer > Senior Lecturer 2 15%
Student > Bachelor 1 8%
Student > Master 1 8%
Other 2 15%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 5 38%
Medicine and Dentistry 2 15%
Pharmacology, Toxicology and Pharmaceutical Science 1 8%
Business, Management and Accounting 1 8%
Neuroscience 1 8%
Other 2 15%
Unknown 1 8%

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 November 2015.
All research outputs
#1,876,987
of 12,300,358 outputs
Outputs from European Journal of Pharmaceutical Sciences
#157
of 1,519 outputs
Outputs of similar age
#56,781
of 321,783 outputs
Outputs of similar age from European Journal of Pharmaceutical Sciences
#11
of 49 outputs
Altmetric has tracked 12,300,358 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,519 research outputs from this source. They receive a mean Attention Score of 4.3. This one has gotten more attention than average, scoring higher than 72% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 321,783 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 49 others from the same source and published within six weeks on either side of this one. This one is in the 32nd percentile – i.e., 32% of its contemporaries scored the same or lower than it.